Treatment of Nonmetastatic Castration Resistant Prostate Cancer

被引：1
|
作者：
Luo, Jia [1 ]
Beer, Tomasz M. [2 ]
Graff, Julie N. [2 ,3 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] VA Portland Hlth Care Syst, Portland, OR USA
来源：
ONCOLOGY-NEW YORK | 2016年 / 30卷 / 04期
关键词：
METASTASIS-FREE SURVIVAL; ANDROGEN-RECEPTOR GENE; ANTIANDROGEN WITHDRAWAL; PHASE-III; MEN; THERAPY; HORMONE; ENZALUTAMIDE; BICALUTAMIDE; COMBINATION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.
引用
收藏
页码：336 / 344
页数：9
相关论文
共 50 条
  • [31] Re: Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2021, 205 (04): : 1226 - 1227
  • [32] Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
    Schultz, Neil M.
    O'Day, Ken
    Sugarman, Rebecca
    Ramaswamy, Krishnan
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (04): : 538 - 549
  • [33] Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer
    Avxentyev, N. A.
    Frolov, M. Yu
    Makarova, Yu, V
    ONKOUROLOGIYA, 2020, 16 (02): : 82 - 96
  • [34] Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan
    Shah, Ruchitbhai
    Botteman, Marc
    Waldeck, Reginald
    FUTURE ONCOLOGY, 2019, 15 (35) : 4069 - 4081
  • [35] DISEASE SPECIFIC COST ANALYSIS OF THE NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER HEALTH STATES
    Yanev, I
    Aprikian, A.
    Nablsi, E.
    Primiani, J.
    Vaillancourt, Z.
    Dragomir, A.
    VALUE IN HEALTH, 2018, 21 : S73 - S73
  • [36] Treatment of nonmetastatic CRPC Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis
    Hadaschik, Boris
    Hellmis, Eva
    UROLOGE, 2021, 60 (06): : 753 - 759
  • [37] PSMA PET–CT redefines nonmetastatic castration-resistant prostate cancer
    Piet Ost
    Nature Reviews Urology, 2020, 17 : 133 - 134
  • [38] Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
    Feng, Felix Y.
    Thomas, Shibu
    Saad, Fred
    Gormley, Michael
    Yu, Margaret K.
    Ricci, Deborah S.
    Rooney, Brendan
    Brookman-May, Sabine
    McCarthy, Sharon
    Olmos, David
    Chowdhury, Simon
    Hadaschik, Boris
    Liu, Yang
    Davicioni, Elai
    Smith, Matthew R.
    Small, Eric J.
    JAMA ONCOLOGY, 2021, 7 (07) : 1005 - 1014
  • [39] Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment
    Srinivas, Sandy
    Mohamed, Ateesha F.
    Appukkuttan, Sreevalsa
    Botteman, Marc
    Ng, Xinyi
    Joshi, Namita
    Tsai, Jui-Hua
    Fang, Jarjieh
    Waldeck, A. Reginald
    Simmons, Stacey J.
    CANCER MEDICINE, 2020, 9 (18): : 6586 - 6596
  • [40] ECONOMIC EVALUATION OF NUBEQAL FOR THE TREATMENT OF ADULT PATIENTS WITH NONMETASTATIC CASTRATION RESISTANT PROSTATE CANCER IN THE MEXICAN CONTEXT
    Cruz, Monroy B.
    Gamez, Ramirez J.
    Corro, A.
    Rely, K.
    VALUE IN HEALTH, 2023, 26 (12) : S123 - S123
12345